Stay updated with breaking news from Ryan hartwell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Silo Wellness benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Psychedelics and mental health company The Series D funding round is being touted as the psychedelics sector’s largest to date. Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel. Apeiron Investment Group and Woodline Partners LP also participated. Atai’s portfolio companies are researching 13 different psychedelic and non-psychedelic compounds for the treatment of a wide range of mental health disorders. Atai is an early investor and holds a significant stake in Compass Pathways (NASDAQ: CMPS). Last November, Atai closed a Series C financing round for $125 million. A spokesperson told Benzinga that the company is expected to list on NASDAQ during 2021, but exact dates are still to be confirmed. ....
Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of Magic Mushrooms Benzinga 3/8/2021 Psychedelics and mental health company Popular Searches The Series D funding round is being touted as the psychedelics sector’s largest to date. Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel. Apeiron Investment Group and Woodline Partners LP also participated. Atai’s portfolio companies are researching 13 different psychedelic and non-psychedelic compounds for the treatment of a wide range of mental health disorders. Atai is an early investor and holds a significant stake in ....
Share: The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:MCUR) (OTCQB:MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research. Ibogaine is a naturally occurring psychoactive compound extracted from the root of the Tabernanthe iboga shrub , native of the Congo and Gabon. 1 The compound offers therapeutic potential for substance use disorders, and is claimed to be among the most powerful anti-addiction drugs, particularly when used with proper supervision and support. However, natural sources of ibogaine are extremely limited since these plants are at risk of extinction due to the growing global demand and environmental pressures t ....